Annual ROE
-47.44%
+10.70%+18.40%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual return on equity is -47.44%, with the most recent change of +10.70% (+18.40%) on December 31, 2023.
- During the last 3 years, VYNE annual ROE has risen by +434.76% (+90.16%).
- VYNE annual ROE is now -193.06% below its all-time high of 50.98%, reached on December 31, 2017.
Performance
VYNE ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-52.79%
-1.25%-2.43%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly return on equity is -52.79%, with the most recent change of -1.25% (-2.43%) on September 30, 2024.
- Over the past year, VYNE quarterly ROE has dropped by -1.25% (-2.43%).
- VYNE quarterly ROE is now -182.92% below its all-time high of 63.66%, reached on September 30, 2017.
Performance
VYNE Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
VYNE ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.4% | -2.4% |
| 3 y3 years | +90.2% | -1.9% |
| 5 y5 years | +66.2% | -1.9% |
VYNE ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +72.1% | -7.0% | +58.5% |
| 5 y | 5-year | at high | +90.2% | -7.0% | +87.8% |
| alltime | all time | -193.1% | +90.2% | -182.9% | +88.6% |
VYNE Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -52.79%(+2.4%) |
| Jun 2024 | - | -51.54%(-19.4%) |
| Mar 2024 | - | -63.96%(-21.3%) |
| Dec 2023 | -47.44%(-18.4%) | -81.22%(-36.2%) |
| Sep 2023 | - | -127.33%(+18.6%) |
| Jun 2023 | - | -107.40%(+29.4%) |
| Mar 2023 | - | -83.01%(+60.2%) |
| Dec 2022 | -58.14%(-65.9%) | -51.81%(+5.0%) |
| Sep 2022 | - | -49.34%(-22.9%) |
| Jun 2022 | - | -63.98%(-11.9%) |
| Mar 2022 | - | -72.66%(-38.0%) |
| Dec 2021 | -170.28%(-64.7%) | -117.21%(-13.4%) |
| Sep 2021 | - | -135.39%(-0.0%) |
| Jun 2021 | - | -135.40%(-63.2%) |
| Mar 2021 | - | -367.45%(-14.7%) |
| Dec 2020 | -482.20% | -430.86%(+17.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | -366.79%(+18.9%) |
| Jun 2020 | - | -308.50%(+187.4%) |
| Mar 2020 | - | -107.33%(+46.7%) |
| Dec 2019 | -74.12%(-47.2%) | -73.16%(+22.0%) |
| Sep 2019 | - | -59.96%(+19.1%) |
| Jun 2019 | - | -50.36%(+25.2%) |
| Mar 2019 | - | -40.22%(-14.9%) |
| Dec 2018 | -140.29%(-375.2%) | -47.27%(-19.8%) |
| Sep 2018 | - | -58.95%(-41.9%) |
| Jun 2018 | - | -101.48%(-78.1%) |
| Mar 2018 | - | -463.86%(-937.6%) |
| Dec 2017 | 50.98%(+6.7%) | 55.38%(-13.0%) |
| Sep 2017 | - | 63.66%(+13.8%) |
| Jun 2017 | - | 55.92%(+59.7%) |
| Mar 2017 | - | 35.02%(+113.1%) |
| Dec 2016 | 47.78%(+65.4%) | 16.43% |
| Dec 2015 | 28.88% | - |
FAQ
- What is VYNE Therapeutics annual return on equity?
- What is the all time high annual ROE for VYNE Therapeutics?
- What is VYNE Therapeutics annual ROE year-on-year change?
- What is VYNE Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly ROE year-on-year change?
What is VYNE Therapeutics annual return on equity?
The current annual ROE of VYNE is -47.44%
What is the all time high annual ROE for VYNE Therapeutics?
VYNE Therapeutics all-time high annual return on equity is 50.98%
What is VYNE Therapeutics annual ROE year-on-year change?
Over the past year, VYNE annual return on equity has changed by +10.70% (+18.40%)
What is VYNE Therapeutics quarterly return on equity?
The current quarterly ROE of VYNE is -52.79%
What is the all time high quarterly ROE for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly return on equity is 63.66%
What is VYNE Therapeutics quarterly ROE year-on-year change?
Over the past year, VYNE quarterly return on equity has changed by -1.25% (-2.43%)